Oragenics (OGEN) Terminates Material Definitive Agreement
Ticker: OGEN · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1174940
Complexity: simple
Sentiment: neutral
Topics: agreement-termination, corporate-governance, strategic-change
TL;DR
**Oragenics (OGEN) just terminated a key agreement, signaling a potential shift in its business outlook.**
AI Summary
Oragenics, Inc. (OGEN) filed an 8-K on January 23, 2024, to report the termination of a material definitive agreement. This filing indicates a significant change in the company's operational or strategic plans, as such agreements often relate to key partnerships, financing, or asset sales. For investors, this matters because the termination of a material agreement can signal a shift in the company's financial health, strategic direction, or future revenue prospects, potentially impacting the stock's valuation.
Why It Matters
The termination of a material definitive agreement can indicate a significant change in Oragenics' business strategy or financial stability, potentially affecting its future growth and profitability.
Risk Assessment
Risk Level: medium — The termination of a material agreement introduces uncertainty about the company's future plans and financial performance, posing a medium risk to investors.
Analyst Insight
A smart investor would monitor Oragenics' subsequent filings and press releases for specific details regarding the terminated agreement and its financial implications before making any investment decisions.
Key Players & Entities
- Oragenics, Inc. (company) — the registrant filing the 8-K
- OGEN (company) — trading symbol for Oragenics, Inc.
- January 23, 2024 (date) — date of earliest event reported and filing date
Forward-Looking Statements
- Oragenics will provide further details on the terminated agreement and its impact in future filings or press releases. (Oragenics, Inc.) — high confidence, target: Q1 2024
- The termination could lead to a re-evaluation of Oragenics' strategic direction. (Oragenics, Inc.) — medium confidence, target: Q2 2024
FAQ
What is the primary purpose of Oragenics' 8-K filing on January 23, 2024?
The primary purpose of Oragenics' 8-K filing on January 23, 2024, is to report the 'Termination of a Material Definitive Agreement' and 'Other Events', as stated in the 'ITEM INFORMATION' section of the filing.
What is Oragenics, Inc.'s trading symbol and on which exchange is it registered?
Oragenics, Inc.'s trading symbol is OGEN, and its Common Stock is registered on the NYSE American exchange, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the state of incorporation for Oragenics, Inc.?
Oragenics, Inc. is incorporated in FL (Florida), as specified under '(State or other jurisdiction of incorporation)' in the filing.
What is the business phone number for Oragenics, Inc.?
The business phone number for Oragenics, Inc. is 813-286-7900, as listed under '(Registrant’s telephone number, including area code)'.
What is the Central Index Key (CIK) for Oragenics, Inc.?
The Central Index Key (CIK) for Oragenics, Inc. is 0001174940, found under 'COMPANY DATA: CENTRAL INDEX KEY'.
Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-23 17:18:59
Key Financial Figures
- $0.001 — l shares of its common stock, par value $0.001 per share, having aggregate offering sa
- $5,000,000 — regate offering sales proceeds of up to $5,000,000 (the "Shares"), through Ladenburg (the
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-003487.txt ( ) — 231KB
- ogen-20240123.xsd (EX-101.SCH) — 3KB
- ogen-20240123_lab.xml (EX-101.LAB) — 33KB
- ogen-20240123_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 23 rd day of January 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer